Daily Sepsis Research Analysis
Three impactful sepsis studies span mechanistic immunology, predictive analytics, and antimicrobial resistance. A Science Immunology paper reveals that TNF can convert efferocytosis into caspase-8-dependent pyroptosis with IL-1β maturation, reframing inflammation in SIRS/sepsis. A multi-database ML model (SAFE-Mo) improves early mortality prediction in sepsis-associated ARDS, and a multicentre neonatal study from India links high MDR rates and off-target empiric therapy to higher mortality.
Summary
Three impactful sepsis studies span mechanistic immunology, predictive analytics, and antimicrobial resistance. A Science Immunology paper reveals that TNF can convert efferocytosis into caspase-8-dependent pyroptosis with IL-1β maturation, reframing inflammation in SIRS/sepsis. A multi-database ML model (SAFE-Mo) improves early mortality prediction in sepsis-associated ARDS, and a multicentre neonatal study from India links high MDR rates and off-target empiric therapy to higher mortality.
Research Themes
- TNF-driven switch from efferocytosis to caspase-8-dependent pyroptosis in SIRS/sepsis
- Machine learning risk stratification for early mortality in sepsis-associated ARDS
- Neonatal sepsis antimicrobial resistance and impact of off-target empiric therapy
Selected Articles
1. TNF switches homeostatic efferocytosis to lytic caspase-8-dependent pyroptosis and IL-1β maturation.
Using TNF-induced SIRS mouse models, the authors show that efferocytosis can switch from an anti-inflammatory program to lytic, caspase-8-dependent pyroptosis with IL-1β maturation. This reveals a mechanism by which TNF reprograms macrophage responses under dysregulated inflammation, challenging the notion of immunologically silent efferocytosis during sepsis/SIRS.
Impact: This study identifies a TNF–caspase-8 pathway that flips efferocytosis into inflammatory pyroptosis, providing a mechanistic link between dysregulated inflammation and cytokine maturation in sepsis/SIRS. It reframes macrophage clearance as a potential driver of inflammation.
Clinical Implications: Targeting the TNF–caspase-8–IL-1β axis may attenuate hyperinflammation in SIRS/sepsis. It also cautions against assuming efferocytosis is always anti-inflammatory in critically ill states.
Key Findings
- TNF reprograms efferocytosis into lytic, caspase-8-dependent pyroptosis.
- This switch promotes IL-1β maturation, linking cell clearance to cytokine activation.
- Findings were demonstrated in mouse models of TNF-induced SIRS.
Methodological Strengths
- Use of in vivo TNF-induced SIRS mouse models to probe mechanism
- Clear mechanistic focus on caspase-8 dependence and IL-1β maturation
Limitations
- Preclinical mouse data; human validation not provided in the abstract
- Abstract is truncated, limiting detailed methodological appraisal
Future Directions: Validate the TNF–caspase-8 pyroptosis pathway in human sepsis samples; test pharmacologic inhibitors of caspase-8 or IL-1 signaling in preclinical sepsis models.
Efferocytosis, wherein phagocytes engulf dead or dying cells, is a critical function of macrophages that supports cellular turnover, tissue repair, and resolution of inflammation. Despite its well-established anti-inflammatory mechanism in homeostasis, whether efferocytosis remains immunologically silent in the context of dysregulated immune responses such as sepsis or systemic inflammatory response syndrome (SIRS) has not been investigated. Here, we used mouse models of tumor necrosis factor (TNF)-induced SIRS and
2. Enhancing early mortality prediction for sepsis-associated acute respiratory distress syndrome patients via optimized machine learning algorithm: development and multiple databases' validation of the SAFE-Mo.
SAFE-Mo, an SVM-based model developed from MIMIC-IV, eICU, and NWICU, outperformed APSIII, SAPS II, SOFA, and CCI for early mortality prediction in sepsis-associated ARDS. External validation and decision curve analysis demonstrated superior discrimination, broader threshold utility, and slight overall risk overestimation.
Impact: Demonstrates a validated, generalizable ML tool that consistently outperforms standard scoring systems for a lethal sepsis phenotype (sepsis-associated ARDS), with an accessible web interface for clinical use.
Clinical Implications: Enables earlier identification of high-risk patients to trigger timely escalation (e.g., prone positioning, conservative fluids, vasopressor titration) and supports benchmarking across centers using risk-adjusted outcomes.
Key Findings
- SAFE-Mo outperformed APSIII, SAPS II, SOFA, and CCI in predicting early mortality.
- Decision curve analysis showed the widest beneficial threshold range and highest net benefit.
- Calibration indicated slight overestimation of mortality risk; key predictors included lactate, urine output, and anion gap.
Methodological Strengths
- Multi-database external validation (MIMIC-IV, eICU, NWICU)
- Comprehensive performance assessment (AUC, calibration, decision curve analysis) with comparison to established scores
Limitations
- Retrospective design with potential residual confounding and dataset shift
- Slight overestimation on calibration suggests need for local recalibration before deployment
Future Directions: Prospective, interventional validation to assess whether SAFE-Mo-guided care improves outcomes; model updating with federated learning and fairness audits across subgroups.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is associated with high mortality, with sepsis accounts for 31-34% of cases. Given the global burden of sepsis (508 cases per 100 000 person-years) and its association with 20% of all global deaths, early mortality prediction in patients with sepsis-associated ARDS is critical. This study developed and validated the Sepsis-associated ARDS Fatality Evaluation Model (SAFE-Mo), a machine learning (ML) model designed to predict early mortality in sepsis-associated ARDS patients, enabling earlier identification of high-risk individuals. METHODS: Data were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV, v3.0), eICU Collaborative Research Database (eICU CRD, v2.0), and Northwest ICU (NWICU, v0.1.0) using Structured Query Language (SQL). SAFE-Mo was constructed using ML algorithm (svmRadialSigma) focusing on median survival days among deceased patients as the primary outcome. The model's performance was validated externally using the MIMIC-IV and eICU CRD database and compared against four commonly used clinical risk assessment models (acute physiology score III (APSIII), simplified acute physiology score II (SAPS II), sequential organ failure assessment (SOFA), Charlson comorbidity index (CCI)). Additionally, NWICU was used to further validate SAFE-Mo's generalization. Discrimination, calibration, and clinical utility were evaluated using area under the curve (AUC), Decision Curve Analysis (DCA), and calibration curves. RESULTS: SAFE-Mo demonstrated superior predictive capability of early mortality compared to traditional models. It showed the largest reasonable risk threshold probability range and highest net benefit. Calibration curves indicated a slight overestimation of mortality risk overall. With our simple SAFE-Mo web page, SAFE-Mo can assist clinicians in identifying high-risk patients early, like patients with unusually high levels of lactate in sepsis-associated ARDS, assessing prognosis, and facilitating risk-adjusted comparisons of center-specific outcomes. Practical advantages include guiding personalized treatment strategies, determining the need for aggressive interventions, and optimizing resource utilization. CONCLUSION: This study utilized the MIMIC-IV, eICU CRD, and NWICU databases to construct and validate a ML model, SAFE-Mo, which predicts early mortality in patients with sepsis-associated ARDS and outperforms traditional prediction models across all metrics. SAFE-Mo can guide clinicians to focus on critical indicators such as lactate, urine output, anion gap, and others, enabling appropriate measures to improve clinical outcomes for high-risk patients.
3. High prevalence of antimicrobial resistance to initial empirical antibiotic therapy in neonatal sepsis in Bengaluru, India-a multicentre study.
In a six-NICU network in Bengaluru, 60% of neonatal sepsis was due to Gram-negative pathogens, predominantly Klebsiella, with high MDR rates. Initial empiric antibiotics covered the pathogen in only 48% of cases, and off-target therapy was associated with more than double the mortality risk.
Impact: Provides actionable local AMR data showing high MDR prevalence and the clinical penalty of off-target empiric therapy in neonatal sepsis, informing antibiotic stewardship and empiric guidelines in LMIC settings.
Clinical Implications: Empiric regimens in similar settings should be re-evaluated toward covering prevalent MDR Gram-negatives (especially Klebsiella/Acinetobacter) while balancing stewardship; rapid diagnostics could mitigate off-target exposure.
Key Findings
- Neonatal sepsis incidence was 3.5% among 6,229 admissions; 60% were Gram-negative.
- Klebsiella (30%) was predominant; MDR rates were high in Gram-negatives (Klebsiella 48%, Acinetobacter 81%, E. coli 45%).
- Empiric antibiotics were on-target in 48% (95% CI 45–58%); off-target therapy doubled mortality risk (RR 2.2, 95% CI 1.06–4.9).
Methodological Strengths
- Multicentre standardized data collection across six NICUs
- Comprehensive organism distribution and resistance profiling with risk analysis for off-target therapy
Limitations
- Observational design within a single metropolitan region limits generalizability
- Blood culture–positive cases only; potential selection bias and under-detection of culture-negative sepsis
Future Directions: Prospective evaluation of revised empiric guidelines and rapid diagnostics; antimicrobial stewardship interventions targeting MDR Gram-negatives in NICUs.
Data about epidemiologic and microbiologic patterns of neonatal sepsis in specific regions of low- and middle-income countries can help improve management and stimulate prevention efforts. We conducted a multicentre study within a large metropolitan region in South India to describe the burden of neonatal sepsis; and identify the antimicrobial sensitivity patterns of causative organisms. In a collaborative network of six neonatal intensive care units, standardized data were collected on every admitted neonate with a positive blood culture from June 2020 to May 2022. The frequency of sepsis, the organisms, antimicrobial resistance patterns, and mortality were analysed. Factors associated with lack of 'on-target' initial empirical antibiotic therapy were identified through univariate and multivariate analysis. Among 6229 admissions, the incidence of sepsis was 3.5%. Klebsiella (30%), Coagulase-negative staphylococcus (13%), and Escherichia coli (10%) were the commonest organisms. The overall incidence of multidrug resistance among Gram-negative organisms was 26%, with organism-specific incidence as follows: Klebsiella (48%), Acinetobacter (81%), and E. coli (45%). The organisms were sensitive to one or more of the initial empirical antibiotics used ('on-target') in 48% [95% confidence interval (CI) 45-58%] of cases. Mortality was higher in those neonates where initial antibiotic therapy was not 'on-target' (Relative risk (RR): 2.2, 95% CI 1.06-4.9). To conclude gram-negative septicaemia constituted 60% of the burden of neonatal sepsis. Klebsiella pneumonia was the predominant organism. Multidrug resistant organisms were highly prevalent. Initial empirical antibiotic therapy was not 'on-target' more than 50% of the time and was associated with higher mortality.